Table 1 Results of the systematic literature review regarding median OS
Authors | Title | Year | Journal | Intervention | Population [n] | Median OS |
|---|---|---|---|---|---|---|
Bardia, A. et al. [6] | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | 2021 | N Engl J Med | SG | 267 | 11.8 months |
Bardia, A. et al. [26] | Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer | 2017 | J Clin Oncol | SG | 69 | 16.6 months |
Sari, M. et al. [36] | Eribulin monotherapy in heavily pretreated metastatic breast cancer patients in real life | 2020 | Indian J Cancer | Eribulin | 7 | 10 months |
Krasniqi, E. et al. [27] | Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial | 2021 | Int J Med Sci | Eribulin | 44 | 11.9 months |
Kazmi, S. et al. [28] | Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine | 2020 | Breast Cancer Res Treat | Eribulin Capecitabine | 66 (Eribulin) 20 (Capecitabine) | 7.0 months (Eribulin) 5.5 months (Capecitabine) |
Ates, O. et al. [37] | Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer | 2016 | J BUON | Eribulin | 7 | 3 months |
Mougalian, SS. et al. [29] | Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting | 2018 | Cancer Med | Eribulin | 127 | 14.7 months |
Miyoshi, Y. et al. [30] | High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician’s choice-in the EMBRACE study | 2020 | Breast Cancer | Eribulin | 27 65* | 9.5 months 9.5 months** |
Valerio, M.R. et al. [31] | Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety | 2021 | Am J Clin Oncol | Eribulin | 38 | 10.8 months |
Decker, T. et al. [39] | VicTORia: a randomised phase II study to compare vinorelbine in combination with the mTOR inhibitor everolimus versus vinorelbine monotherapy for second-line chemotherapy in advanced HER2-negative breast cancer | 2019 | Breast Cancer Res Treat | Vinorelbine | 12 | 9.44 months |
Pedersini, R. et al. [38] | Eribulin in Heavily Pretreated Metastatic Breast Cancer Patients in the Real World: A Retrospective Study | 2018 | Oncology | Eribulin | 8 | 7.43 months |
Aogi, K. et al. [32] | A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer | 2012 | Ann Oncol | Eribulin | 22 | 10.68 months |
Mougalian, SS. et al. [33] | Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States | 2021 | Adv Ther | Eribulin | 256 | 9.8 months |
Twelves, C. et al. [34] | Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer | 2016 | Breast Cancer (Auckl) | Eribulin Capecitabine | 106 (Eribulin) 102 (Capecitabine) | 15.2 months (Eribulin) 9.2 months (Capecitabine) |
Chan, A. et al. [35] | Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia | 2022 | Asia Pac J Clin Oncol. | Eribulin | 51*** | 4.3 months |